Elsevier Business Intelligence, publisher of PharmAsia News, IN VIVO and 'The Pink Sheet', has announced the agenda for Windhover's 2nd PharmAsia Summit, scheduled for October 25-26, 2010. This year's Summit will bring top biopharma leaders from Asia and the US to San Francisco to share what works and what doesn't in China, India, Japan and the Pacific Rim.
At the PharmAsia Summit, participants will get an opportunity to hear Asia strategies and case studies from industry leading experts on deal making, commercial strategy, outsourcing, regulatory risks, IP protection, and pricing and reimbursement. Confirmed speakers include Biogen Idec's Gunther Winkler, Senior VP Asia Pacific & Global Government Strategy; Merck's Ramesh Subrahmanian, Senior VP & President of Asia Pacific Human Health; Takeda Research Investment CEO Graeme Martin; Pfizer's Neil Gibson, CSO Oncology Research; Gilead's Clifford Samuel, VP International Access; Advinus Therapeutics CEO, Rashmi Barbhaiya; and IMS Asia Pacific VP, Jan Willem Eleveld, among others.
Attendees will, in addition, learn the latest on China healthcare reform, U.S. FDA actions in China and India, case studies on Japanese deal making with U.S. biotechs, novel Asia investment strategies, tips for launching innovative therapies in India and China, opportunities for pre-competitive collaboration that will help de-risk R&D, and finding the right partner in Asia. Moreover, they can catch up on the latest Asian market trends and data from IMS Health, which sees China becoming the third largest pharma market in 2011 and predicts explosive growth in other hot Asia markets like India and Korea.
Search for more Conferences
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
